Mesothelioma Chemotherapy: Comparison of cisplatin & carboplatin

A mesothelioma articles recently published in scientific journals that examine the lung cancer benefits and costs and Pemetrexed combined with cisplatin and carboplatin chemotherapy Pemetrexed for mesothelioma.

Cisplatin combination chemotherapy and Pemetrexed is one of several options that chemotherapy has proved quite successful in the treatment of patients with malignant pleural mesothelioma / malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no treatment and treatment for malignant mesothelioma cancer without the side effects that are not desirable.

In these journals the researchers noted that "there are two phases of randomized studies in phase III shows the benefit for the prognosis of mesothelioma in the use of antifolates such as raltitrexed or Pemetrexed, when combined with cisplatin. The study has demonstrated an absolute improvement in overall survival an average of 2.6 and 2.8 months, compared with single treatment for cisplatin. This makes a lot of institutions using cisplatin and Pemetrexed as the standard palliative chemotherapy treatment for malignant pleural mesothelioma. "

Unfortunately, the combination of cisplatin and Pemetrexed produce toxic effects that are not desirable and this encouraged the researchers to study other chemotherapy drugs in combination with Pemetrexed. The researchers said, "Recently, two phase II trial has evaluated the efficacy of carboplatin and will Pemetrexed in MPM. Both studies showed overall response rates 18.6 and 25%, with survival rates average 12.7 and 14 months. As a continuation of these results, we have made a retrospective analysis of MPM patients treated with carboplatin and Pemetrexed in our institutions. "

In an effort to find a combination of chemotherapy mesothelioma with minimal toxicity and side effects, the researchers investigated further by replacing cisplatin with carboplatin when paired with Pemetrexed. By using a retrospective approach, the researchers evaluated 49 cases of malignant pleural mesothelioma who were given a combination of carboplatin and Pemetrexed and compare the results with the data giving cisplatin combination chemotherapy with Pemetrexed.

The level of disease control (known by its lack of signs of progressive mesothelioma by CT scan) for the patients was 69 percent, and a partial response and stable disease percentage of 28 percent and 41 percent. Clinical improvement shown in figure 69 per cent, the majority of patients reported increased profits after two cycles of chemotherapy. Generally low toxicity and better than the toxicity of cisplatin with Pemetrexed.

The average time of treatment failure was 4.6 months. The average overall survival in this study is 14 months, which compared with the cisplatin-pemetrexed for 12.1 months. Researchers argued, "In conclusion, our data show the combination of carboplatin and Pemetrexed may be an option in the treatment of mesothelioma, especially in patients who have problems with the use of cisplatin."

DOWNLOAD HERE :


Lowongan kerja terbaru dan up to date
Kunjungi Vacancy pusatnya job bermutu.